These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 16365973)

  • 21. Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
    Haire B; Folayan MO; Hankins C; Sugarman J; McCormack S; Ramjee G; Warren M
    Dev World Bioeth; 2013 Aug; 13(2):87-94. PubMed ID: 23725227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiretrovirals for HIV prevention: translating promise into praxis.
    Mayer KH
    Lancet; 2011 Jul; 378(9787):206-8. PubMed ID: 21763922
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
    Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
    J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AIDS drug trial turned away; protests by prostitutes in Cambodia ended Tenofovir testing.
    Cha AE
    Washington Post; 2006 May; ():A10, A14. PubMed ID: 16856292
    [No Abstract]   [Full Text] [Related]  

  • 26. Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection.
    DeChristoforo R; Penzak SR
    Am J Health Syst Pharm; 2004 Jan; 61(1):86-98; quiz 99-100. PubMed ID: 14725126
    [No Abstract]   [Full Text] [Related]  

  • 27. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
    AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
    [No Abstract]   [Full Text] [Related]  

  • 28. Two-year data released on Viread for chronic hepatitis B.
    AIDS Patient Care STDS; 2008 Nov; 22(11):921. PubMed ID: 19025487
    [No Abstract]   [Full Text] [Related]  

  • 29. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
    Burty C; Prazuck T; Truchetet F; Christian B; Penalba C; Salmon-Ceron D; Yazdanpanah Y; May T; Rabaud C
    AIDS Patient Care STDS; 2010 Jan; 24(1):1-3. PubMed ID: 20095911
    [No Abstract]   [Full Text] [Related]  

  • 30. Unethical clinical trials in Thailand: a community response.
    Jintarkanon S; Nakapiew S; Tienudom N; Suwannawong P; Wilson D
    Lancet; 2005 May 7-13; 365(9471):1617-8. PubMed ID: 15885287
    [No Abstract]   [Full Text] [Related]  

  • 31. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
    Khanlou H; Yeh V; Guyer B; Farthing C
    AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
    van Bömmel F; Wünsche T; Mauss S; Reinke P; Bergk A; Schürmann D; Wiedenmann B; Berg T
    Hepatology; 2004 Dec; 40(6):1421-5. PubMed ID: 15565615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
    Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
    Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scar undone: long-term therapy of hepatitis B.
    Tana MM; Hoofnagle JH
    Lancet; 2013 Feb; 381(9865):433-4. PubMed ID: 23234726
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 36. Failure of combination abacavir + tenofovir + lamivudine (3TC).
    AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
    Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
    Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
    Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
    HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
    [No Abstract]   [Full Text] [Related]  

  • 39. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
    Stephenson J
    JAMA; 2011 May; 305(19):1952. PubMed ID: 21586708
    [No Abstract]   [Full Text] [Related]  

  • 40. Tenofovir Gel to Prevent HSV-2 Infection.
    Abdool Karim SS; Abdool Karim Q; Gengiah TN
    N Engl J Med; 2015 Nov; 373(20):1980-1. PubMed ID: 26559584
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.